{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:59:22Z","timestamp":1790801962211,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,8]]},"DOI":"10.7759\/cureus.85563","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:17:24Z","timestamp":1749403044000},"source":"Crossref","is-referenced-by-count":7,"title":["The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Nammas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World mental health report. transforming mental health for all. (2022). https:\/\/www.who.int\/publications\/i\/item\/9789240049338."},{"key":"ref2","article-title":"Global burden of disease 2021: mental health messages","volume":"11","year":"2024","unstructured":"Global burden of disease 2021. mental health messages. Lancet Psychiatry. 2024, 11:","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201642951","article-title":"The economic costs of mental disorders: do our societies react appropriately to the burden of mental disorders?","volume":"17","author":"Trautmann S","year":"2016","unstructured":"Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: do our societies react appropriately to the burden of mental disorders?. EMBO Rep. 2016, 17:1245-9. 10.15252\/embr.201642951","journal-title":"EMBO Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00505-2","article-title":"Estimating the true global burden of mental illness","volume":"3","author":"Vigo D","year":"2016","unstructured":"Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016, 3:171-8. 10.1016\/S2215-0366(15)00505-2","journal-title":"Lancet Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.14384","article-title":"Strategic targeting of advance care planning interventions: the Goldilocks phenomenon","volume":"174","author":"Billings JA","year":"2014","unstructured":"Billings JA, Bernacki R. Strategic targeting of advance care planning interventions: the Goldilocks phenomenon. JAMA Intern Med. 2014, 174:620-4. 10.1001\/jamainternmed.2013.14384","journal-title":"JAMA Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford HA","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, et al.. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013, 382:1575-86. 10.1016\/S0140-6736(13)61611-6","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge WM","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012, 32:1959-72. 10.1038\/jcbfm.2012.126","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref8","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench J","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010, 81:617-22.","journal-title":"Am Fam Physician"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134195","article-title":"Inappropriate medications use and polypharmacy among older adults with anxiety disorder","volume":"12","author":"Alwhaibi M","year":"2023","unstructured":"Alwhaibi M. Inappropriate medications use and polypharmacy among older adults with anxiety disorder. J Clin Med. 2023, 12:10.3390\/jcm12134195","journal-title":"J Clin Med"},{"key":"ref10","article-title":"Prescribing Guidelines in Psychiatry. Fourteenth Edition","author":"Taylor DM","year":"2021","unstructured":"Taylor DM, Barnes TR, Young AH. Prescribing Guidelines in Psychiatry. Fourteenth Edition. Wiley Blackwell, Hoboken, NJ; 2021."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1743-8977-7-3","article-title":"Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging","volume":"7","author":"Bhaskar S","year":"2010","unstructured":"Bhaskar S, Tian F, Stoeger T, et al.. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010, 7:10.1186\/1743-8977-7-3","journal-title":"Part Fibre Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel T","year":"2012","unstructured":"Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012, 64:701-5. 10.1016\/j.addr.2011.12.006","journal-title":"Adv Drug Deliv Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices","volume":"21","author":"Jain RA","year":"2000","unstructured":"Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000, 21:2475-90. 10.1016\/S0142-9612(00)00115-0","journal-title":"Biomaterials"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.01.007","article-title":"Targeting collagen for diagnostic imaging and therapeutic delivery","volume":"240","author":"Wahyudi H","year":"2016","unstructured":"Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016, 240:323-31. 10.1016\/j.jconrel.2016.01.007","journal-title":"J Control Release"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2004.01.008","article-title":"1,4,8-trimethylfuro[2,3-H]quinolin-2(1H)-one, a new furocoumarin bioisoster","volume":"39","author":"Marzano C","year":"2004","unstructured":"Marzano C, Chilin A, Baccichetti F, Bettio F, Guiotto A, Miolo G, Bordin F. 1,4,8-trimethylfuro[2,3-H]quinolin-2(1H)-one, a new furocoumarin bioisoster. Eur J Med Chem. 2004, 39:411-9. 10.1016\/j.ejmech.2004.01.008","journal-title":"Eur J Med Chem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9009-8","article-title":"Prodrug approaches for CNS delivery","volume":"10","author":"Rautio J","year":"2008","unstructured":"Rautio J, Laine K, Gynther M, Savolainen J. Prodrug approaches for CNS delivery. AAPS J. 2008, 10:92-102. 10.1208\/s12248-008-9009-8","journal-title":"AAPS J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111031","article-title":"Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products","volume":"12","author":"Markovic M","year":"2020","unstructured":"Markovic M, Ben-Shabat S, Dahan A. Prodrugs for improved drug delivery: lessons learned from recently developed and marketed products. Pharmaceutics. 2020, 12:10.3390\/pharmaceutics12111031","journal-title":"Pharmaceutics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics7040438","article-title":"Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum","volume":"7","author":"Alkilani AZ","year":"2015","unstructured":"Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015, 7:438-70. 10.3390\/pharmaceutics7040438","journal-title":"Pharmaceutics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1918","article-title":"Transferosomes as a transdermal drug delivery system: dermal kinetics and recent developments","volume":"16","author":"Matharoo N","year":"2024","unstructured":"Matharoo N, Mohd H, Michniak-Kohn B. Transferosomes as a transdermal drug delivery system: dermal kinetics and recent developments. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024, 16:10.1002\/wnan.1918","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1515\/tnsci-2022-0258","article-title":"Nanotechnology-based drug delivery for the treatment of CNS disorders","volume":"13","author":"Mittal KR","year":"2022","unstructured":"Mittal KR, Pharasi N, Sarna B, et al.. Nanotechnology-based drug delivery for the treatment of CNS disorders. Transl Neurosci. 2022, 13:527-46. 10.1515\/tnsci-2022-0258","journal-title":"Transl Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2009.11.4\/kevers","article-title":"Personalized medicine in psychiatry: ethical challenges and opportunities","volume":"11","author":"Evers K","year":"2009","unstructured":"Evers K. Personalized medicine in psychiatry: ethical challenges and opportunities. Dialogues Clin Neurosci. 2009, 11:427-34. 10.31887\/DCNS.2009.11.4\/kevers","journal-title":"Dialogues Clin Neurosci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.233","article-title":"VGF function in depression and antidepressant efficacy","volume":"23","author":"Jiang C","year":"2018","unstructured":"Jiang C, Lin WJ, Sadahiro M, et al.. VGF function in depression and antidepressant efficacy. Mol Psychiatry. 2018, 23:1632-42. 10.1038\/mp.2017.233","journal-title":"Mol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101248","article-title":"The future of pharmaceuticals: artificial intelligence in drug discovery and development","author":"Fu C","year":"2025","unstructured":"Fu C, Chen Q. The future of pharmaceuticals: artificial intelligence in drug discovery and development. J Pharm Anal. 2025, 10.1016\/j.jpha.2025.101248","journal-title":"J Pharm Anal"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.04.020","article-title":"Quantitative analysis for lipophilic drug transport through a model lipid membrane with membrane retention","volume":"134","author":"Lee Y","year":"2019","unstructured":"Lee Y, Choi SQ. Quantitative analysis for lipophilic drug transport through a model lipid membrane with membrane retention. Eur J Pharm Sci. 2019, 134:176-84. 10.1016\/j.ejps.2019.04.020","journal-title":"Eur J Pharm Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.03.019","article-title":"Effect of pullulan as additive to the synthetic polymeric coating blend Eudragit NM-L55 on the properties of the resulting films","volume":"109","author":"Sriganaranjan P","year":"2020","unstructured":"Sriganaranjan P, Leopold CS. Effect of pullulan as additive to the synthetic polymeric coating blend Eudragit NM-L55 on the properties of the resulting films. J Pharm Sci. 2020, 109:2166-72. 10.1016\/j.xphs.2020.03.019","journal-title":"J Pharm Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.90101","article-title":"Is propolis safe as an alternative medicine?","volume":"3","author":"Miguel MG","year":"2011","unstructured":"Miguel MG, Antunes MD. Is propolis safe as an alternative medicine?. J Pharm Bioallied Sci. 2011, 3:479-95. 10.4103\/0975-7406.90101","journal-title":"J Pharm Bioallied Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva C","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016, 235:34-47. 10.1016\/j.jconrel.2016.05.044","journal-title":"J Control Release"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/2230-973X.96920","article-title":"Drug delivery systems: an updated review","volume":"2","author":"Tiwari G","year":"2012","unstructured":"Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: an updated review. Int J Pharm Investig. 2012, 2:2-11. 10.4103\/2230-973X.96920","journal-title":"Int J Pharm Investig"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2016.08.033","article-title":"Development of risperidone liposomes for brain targeting through intranasal route","volume":"163","author":"Narayan R","year":"2016","unstructured":"Narayan R, Singh M, Ranjan O, Nayak Y, Garg S, Shavi GV, Nayak UY. Development of risperidone liposomes for brain targeting through intranasal route. Life Sci. 2016, 163:38-45. 10.1016\/j.lfs.2016.08.033","journal-title":"Life Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1615\/critrevtherdrugcarriersyst.v20.i5.20","article-title":"Polymeric micelles for delivery of poorly water-soluble compounds","volume":"20","author":"Kwon GS","year":"2003","unstructured":"Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003, 20:357-403. 10.1615\/critrevtherdrugcarriersyst.v20.i5.20","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-3659(01)00299-1","article-title":"Structure and design of polymeric surfactant-based drug delivery systems","volume":"73","author":"Torchilin VP","year":"2001","unstructured":"Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001, 73:137-72. 10.1016\/s0168-3659(01)00299-1","journal-title":"J Control Release"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1403511","article-title":"Progress of nanoparticle drug delivery system for the treatment of glioma","volume":"12","author":"Lai G","year":"2024","unstructured":"Lai G, Wu H, Yang K, et al.. Progress of nanoparticle drug delivery system for the treatment of glioma. Front Bioeng Biotechnol. 2024, 12:10.3389\/fbioe.2024.1403511","journal-title":"Front Bioeng Biotechnol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.855019","article-title":"pH-responsive polymer nanomaterials for tumor therapy","volume":"12","author":"Chu S","year":"2022","unstructured":"Chu S, Shi X, Tian Y, et al.. pH-responsive polymer nanomaterials for tumor therapy. Front Oncol. 2022, 12:10.3389\/fonc.2022.855019","journal-title":"Front Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2019.16116","article-title":"Novel drug delivery system based on ginsenoside Rb1 loaded to chitosan\/alginate nanocomposite films","volume":"19","author":"Hoang T","year":"2019","unstructured":"Hoang T, Ramadass K, Loc TT, et al.. Novel drug delivery system based on ginsenoside Rb1 loaded to chitosan\/alginate nanocomposite films. J Nanosci Nanotechnol. 2019, 19:3293-300. 10.1166\/jnn.2019.16116","journal-title":"J Nanosci Nanotechnol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.03.008","article-title":"Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy","volume":"20","author":"Oleshkevich E","year":"2019","unstructured":"Oleshkevich E, Morancho A, Saha A, et al.. Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy. Nanomedicine. 2019, 20:10.1016\/j.nano.2019.03.008","journal-title":"Nanomedicine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz MR","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008, 26:1261-8. 10.1038\/nbt.1504","journal-title":"Nat Biotechnol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v64n1211","article-title":"The economic burden of depression in the United States: how did it change between 1990 and 2000?","volume":"64","author":"Greenberg PE","year":"2003","unstructured":"Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry. 2003, 64:1465-75. 10.4088\/jcp.v64n1211","journal-title":"J Clin Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2174\/1567201816666190201143457","article-title":"Topical and transdermal drug delivery: from simple potions to smart technologies","volume":"16","author":"Benson HA","year":"2019","unstructured":"Benson HA, Grice JE, Mohammed Y, Namjoshi S, Roberts MS. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019, 16:444-60. 10.2174\/1567201816666190201143457","journal-title":"Curr Drug Deliv"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.04.005","article-title":"Microneedles for drug and vaccine delivery","volume":"64","author":"Kim YC","year":"2012","unstructured":"Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012, 64:1547-68. 10.1016\/j.addr.2012.04.005","journal-title":"Adv Drug Deliv Rev"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.09.014","article-title":"Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors","volume":"220","author":"Oh Y","year":"2015","unstructured":"Oh Y, Swierczewska M, Kim TH, et al.. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors. J Control Release. 2015, 220:671-81. 10.1016\/j.jconrel.2015.09.014","journal-title":"J Control Release"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121188","article-title":"Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques","volume":"12","author":"Vigata M","year":"2020","unstructured":"Vigata M, Meinert C, Hutmacher DW, et al.. Hydrogels as drug delivery systems: a review of current characterization and evaluation techniques. Pharmaceutics. 2020, 12:10.3390\/pharmaceutics12121188","journal-title":"Pharmaceutics"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio J","year":"2008","unstructured":"Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, J\u00e4rvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008, 7:255-70. 10.1038\/nrd2468","journal-title":"Nat Rev Drug Discov"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present - a pharmacological and clinical perspective","volume":"27","author":"Heal DJ","year":"2013","unstructured":"Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol. 2013, 27:479-96. 10.1177\/0269881113482532","journal-title":"J Psychopharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich FP","year":"2008","unstructured":"Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008, 21:70-83. 10.1021\/tx700079z","journal-title":"Chem Res Toxicol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou Y","year":"2018","unstructured":"Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018, 270:290-303. 10.1016\/j.jconrel.2017.12.015","journal-title":"J Control Release"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen H","year":"2017","unstructured":"Chen H, Zhang W, Zhu G, Xie J, Chen X. Rethinking cancer nanotheranostics. Nat Rev Mater. 2017, 2:10.1038\/natrevmats.2017.24","journal-title":"Nat Rev Mater"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000691","article-title":"Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia","volume":"37","author":"Hard ML","year":"2017","unstructured":"Hard ML, Mills RJ, Sadler BM, et al.. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017, 37:289-95. 10.1097\/JCP.0000000000000691","journal-title":"J Clin Psychopharmacol"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-006-9906-4","article-title":"Application of micro- and nano-electromechanical devices to drug delivery","volume":"23","author":"Staples M","year":"2006","unstructured":"Staples M, Daniel K, Cima MJ, et al.. Application of micro- and nano-electromechanical devices to drug delivery. Pharmaceutical Research. 2006, 23:847-63.","journal-title":"Pharmaceutical Research"},{"key":"ref49","doi-asserted-by":"crossref","DOI":"10.1007\/s11948-021-00302-z","article-title":"Digital technologies for schizophrenia management: a descriptive review","volume":"27","author":"Chivilgina O","year":"2021","unstructured":"Chivilgina O, Elger BS, Jotterand F. Digital technologies for schizophrenia management: a descriptive review. Sci Eng Ethics. 2021, 27:","journal-title":"Sci Eng Ethics"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2196\/16194","article-title":"An integrated brain-machine interface platform with thousands of channels","volume":"21","author":"Musk E","year":"2019","unstructured":"Musk E. An integrated brain-machine interface platform with thousands of channels. J Med Internet Res. 2019, 21:10.2196\/16194","journal-title":"J Med Internet Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25225294","article-title":"Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: advantages and limitations","volume":"25","author":"Zorkina Y","year":"2020","unstructured":"Zorkina Y, Abramova O, Ushakova V, et al.. Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: advantages and limitations. Molecules. 2020, 25:10.3390\/molecules25225294","journal-title":"Molecules"},{"key":"ref52","article-title":"Asenapine transdermal patch for the management of schizophrenia","volume":"50","author":"Zhou M","year":"2020","unstructured":"Zhou M, Derakhshanian S, Rath A, et al.. Asenapine transdermal patch for the management of schizophrenia. Psychopharmacol Bull. 2020, 50:60-82.","journal-title":"Psychopharmacol Bull"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca PM","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013, 13:10.1186\/1471-244X-13-340","journal-title":"BMC Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030246","article-title":"Evaluations of quality by design (QbD) elements impact for developing niosomes as a promising topical drug delivery platform","volume":"12","author":"Shah P","year":"2020","unstructured":"Shah P, Goodyear B, Haq A, Puri V, Michniak-Kohn B. Evaluations of quality by design (QbD) elements impact for developing niosomes as a promising topical drug delivery platform. Pharmaceutics. 2020, 12:10.3390\/pharmaceutics12030246","journal-title":"Pharmaceutics"},{"key":"ref55","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger UM","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013, 138:103-41.","journal-title":"Pharmacol Ther"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks JK","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015, 98:127-34. 10.1002\/cpt.147","journal-title":"Clin Pharmacol Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721120-00004","article-title":"Role of the melatonin system in the control of sleep: therapeutic implications","volume":"21","author":"Pandi-Perumal SR","year":"2007","unstructured":"Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007, 21:995-1018. 10.2165\/00023210-200721120-00004","journal-title":"CNS Drugs"},{"key":"ref58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2009.04.620","article-title":"Prodrugs: bridging pharmacodynamic\/pharmacokinetic gaps","volume":"13","author":"Testa B","year":"2009","unstructured":"Testa B. Prodrugs: bridging pharmacodynamic\/pharmacokinetic gaps. Curr Opin Chem Biol. 2009, 13:338-44.","journal-title":"Curr Opin Chem Biol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.08.008","article-title":"Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?","volume":"71","author":"Kreuter J","year":"2014","unstructured":"Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?. Adv Drug Deliv Rev. 2014, 71:2-14. 10.1016\/j.addr.2013.08.008","journal-title":"Adv Drug Deliv Rev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.04.003","article-title":"Cullin-RING ligase 5: functional characterization and its role in human cancers","volume":"67","author":"Zhao Y","year":"2020","unstructured":"Zhao Y, Xiong X, Sun Y. Cullin-RING ligase 5: functional characterization and its role in human cancers. Semin Cancer Biol. 2020, 67:61-79. 10.1016\/j.semcancer.2020.04.003","journal-title":"Semin Cancer Biol"},{"key":"ref61","article-title":"Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery","volume":"18","author":"Majumder J","year":"2020","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2020, 18:205-27.","journal-title":"Expert Opin Drug Deliv"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.124828","article-title":"Stimuli-responsive nanogels: a smart material for biomedical applications","volume":"403","author":"Chakroborty S","year":"2024","unstructured":"Chakroborty S, Nath N, Mahal A, et al.. Stimuli-responsive nanogels: a smart material for biomedical applications. J Mol Liq. 2024, 403:","journal-title":"J Mol Liq"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2014.0116","article-title":"Developing urinary metabolomic signatures as early bladder cancer diagnostic markers","volume":"19","author":"Shen C","year":"2015","unstructured":"Shen C, Sun Z, Chen D, et al.. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS. 2015, 19:1-11. 10.1089\/omi.2014.0116","journal-title":"OMICS"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2020.33","article-title":"Children and young people who die by suicide: childhood-related antecedents, gender differences and service contact","volume":"6","author":"Rodway C","year":"2020","unstructured":"Rodway C, Tham SG, Ibrahim S, Turnbull P, Kapur N, Appleby L. Children and young people who die by suicide: childhood-related antecedents, gender differences and service contact. BJPsych Open. 2020, 6:10.1192\/bjo.2020.33","journal-title":"BJPsych Open"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac014","article-title":"Primary nonadherence to antipsychotic treatment among persons with schizophrenia","volume":"48","author":"Lieslehto J","year":"2013","unstructured":"Lieslehto J, Tiihonen J, L\u00e4hteenvuo M, et al.. Primary nonadherence to antipsychotic treatment among persons with schizophrenia. Schizophr Bull. 2013, 48:655-63. 10.1093\/schbul\/sbac014","journal-title":"Schizophr Bull"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura S","year":"2013","unstructured":"Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013, 12:991-1003. 10.1038\/nmat3776","journal-title":"Nat Mater"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114824","article-title":"Current and future directions of drug delivery for the treatment of mental illnesses","volume":"197","author":"Brewster PR","year":"2023","unstructured":"Brewster PR, Bari MI, Walker GM, et al.. Current and future directions of drug delivery for the treatment of mental illnesses.  Adv Drug Deliv Rev. 2023, 197:10.1016\/j.addr.2023.114824","journal-title":"Adv Drug Deliv Rev"},{"key":"ref68","unstructured":"Step 2. preclinical research. (2022). Accessed: May 19, 2025: https:\/\/www.fda.gov\/patients\/drug-development-process\/step-2-preclinical-research."},{"key":"ref69","unstructured":"Drug products, including biological products, that contain nanomaterials - guidance for industry. (2022). Accessed. May 19, 2025: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-products-including-biological-products-...."},{"key":"ref70","unstructured":"European Medicines Agency. pre-authorisation evaluation of medicines for human use. (2006). Accessed: May 19, 2025: https:\/\/etp-nanomedicine.eu\/wp-content\/uploads\/2018\/10\/reflection-paper-nanotechnology-based-medicinal-products-human...."},{"key":"ref71","unstructured":"Pharmaceuticals and Medical Devices Agency. Accessed. May 19, 2025: https:\/\/www.pmda.go.jp\/english\/review-services\/outline\/0001.html."},{"key":"ref72","unstructured":"National Medical Products Administration. Accessed. May 19, 2025: https:\/\/english.nmpa.gov.cn."},{"key":"ref73","unstructured":"Nanotechnology Programs at FDA. Accessed. May 19, 2025: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/nanotechnology-programs-fda."},{"key":"ref74","unstructured":"European Medicines Agency. supporting innovation. Accessed: May 19, 2025: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/supporting-innovation."},{"key":"ref75","unstructured":"ICH guideline M13A on bioequivalence for immediate-release solid oral dosage forms - scientific guideline. (2023). Accessed. May 19, 2025: https:\/\/www.ema.europa.eu\/en\/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-g...."},{"key":"ref76","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2023-300670","article-title":"Digital mental health: challenges and next steps","volume":"26","author":"Smith KA","year":"2023","unstructured":"Smith KA, Blease C, Faurholt-Jepsen M, et al.. Digital mental health: challenges and next steps. BMJ Ment Health. 2023, 26:","journal-title":"BMJ Ment Health"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2020.01.016","article-title":"Shifts in patients' question-asking behaviour between 2007 and 2016: an observational study of video-recorded general practice consultations","volume":"103","author":"Meijers MC","year":"2020","unstructured":"Meijers MC, Potappel A, Kloek C, Hartman TO, Spreeuwenberg P, van Dulmen S, Noordman J. Shifts in patients' question-asking behaviour between 2007 and 2016: an observational study of video-recorded general practice consultations. Patient Educ Couns. 2020, 103:1168-75. 10.1016\/j.pec.2020.01.016","journal-title":"Patient Educ Couns"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.2196\/14567","article-title":"Objective user engagement with mental health apps: systematic search and panel-based usage analysis","volume":"21","author":"Baumel A","year":"2019","unstructured":"Baumel A, Muench F, Edan S, Kane JM. Objective user engagement with mental health apps: systematic search and panel-based usage analysis. J Med Internet Res. 2019, 21:10.2196\/14567","journal-title":"J Med Internet Res"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2095","article-title":"Patient perceptions of telehealth primary care video visits","volume":"15","author":"Powell RE","year":"2017","unstructured":"Powell RE, Henstenburg JM, Cooper G, Hollander JE, Rising KL. Patient perceptions of telehealth primary care video visits. Ann Fam Med. 2017, 15:225-9. 10.1370\/afm.2095","journal-title":"Ann Fam Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181cc0366","article-title":"Mental health treatment seeking among older adults with depression: the impact of stigma and race","volume":"18","author":"Conner KO","year":"2010","unstructured":"Conner KO, Copeland VC, Grote NK, Koeske G, Rosen D, Reynolds CF 3rd, Brown C. Mental health treatment seeking among older adults with depression: the impact of stigma and race. Am J Geriatr Psychiatry. 2010, 18:531-43. 10.1097\/JGP.0b013e3181cc0366","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref81","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyac058","article-title":"Challenges and strategies for the recruitment of patients with schizophrenia in a research setting","volume":"25","author":"Deckler E","year":"2022","unstructured":"Deckler E, Ferland M, Brazis S, et al.. Challenges and strategies for the recruitment of patients with schizophrenia in a research setting. Int J Neuropsychopharmacol. 2022, 25:924-32.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref82","doi-asserted-by":"crossref","DOI":"10.3961\/jpmph.23.592","article-title":"The role of pharmacists\u2019 interventions in increasing medication adherence of patients with epilepsy: a scoping review","volume":"57","author":"Ernawati I","year":"2024","unstructured":"Ernawati I, Yasin NM, Setyopranoto I, et al.. The role of pharmacists\u2019 interventions in increasing medication adherence of patients with epilepsy: a scoping review. J Prev Med Public Health. 2024, 57:212-22.","journal-title":"J Prev Med Public Health"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens B","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al.. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012, 73:691-705. 10.1111\/j.1365-2125.2012.04167.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.2196\/26257","article-title":"Prognosis score system to predict survival for COVID-19 cases: a Korean nationwide cohort study","volume":"23","author":"Cho SY","year":"2021","unstructured":"Cho SY, Park SS, Song MK, Bae YY, Lee DG, Kim DW. Prognosis score system to predict survival for COVID-19 cases: a Korean nationwide cohort study. J Med Internet Res. 2021, 23:10.2196\/26257","journal-title":"J Med Internet Res"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibz164","article-title":"Pragmatic measures for implementation research: development of the Psychometric and Pragmatic Evidence Rating Scale (PAPERS)","volume":"11","author":"Stanick CF","year":"2021","unstructured":"Stanick CF, Halko HM, Nolen EA, et al.. Pragmatic measures for implementation research: development of the Psychometric and Pragmatic Evidence Rating Scale (PAPERS). Transl Behav Med. 2021, 11:11-20. 10.1093\/tbm\/ibz164","journal-title":"Transl Behav Med"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2022.03.210459","article-title":"Patient perceptions of video visits in a fee-for-service model","volume":"35","author":"Mohan S","year":"2022","unstructured":"Mohan S, Lin W, Orozco FR, Robinson J, Mahoney A. Patient perceptions of video visits in a fee-for-service model. J Am Board Fam Med. 2022, 35:497-506. 10.3122\/jabfm.2022.03.210459","journal-title":"J Am Board Fam Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1111\/ppc.12019","article-title":"Evaluation of an innovative late-life depression training program","volume":"50","author":"Smith M","year":"2014","unstructured":"Smith M, Stolder ME, Liu MF. Evaluation of an innovative late-life depression training program. Perspect Psychiatr Care. 2014, 50:19-26. 10.1111\/ppc.12019","journal-title":"Perspect Psychiatr Care"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201800519","article-title":"User engagement in mental health apps: a review of measurement, reporting, and validity","volume":"70","author":"Ng MM","year":"2019","unstructured":"Ng MM, Firth J, Minen M, Torous J. User engagement in mental health apps: a review of measurement, reporting, and validity. Psychiatr Serv. 2019, 70:538-44. 10.1176\/appi.ps.201800519","journal-title":"Psychiatr Serv"},{"key":"ref89","doi-asserted-by":"crossref","DOI":"10.2196\/24055","article-title":"Perspectives of trial staff on the barriers to recruitment in a digital intervention for psychosis and how to work around them: qualitative study within a trial","volume":"8","author":"Allan S","year":"2021","unstructured":"Allan S, Mcleod H, Bradstreet S, et al.. Perspectives of trial staff on the barriers to recruitment in a digital intervention for psychosis and how to work around them: qualitative study within a trial. JMIR Hum Factors. 2021, 8:","journal-title":"JMIR Hum Factors"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane JM","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013, 12:216-26. 10.1002\/wps.20060","journal-title":"World Psychiatry"},{"key":"ref91","article-title":"Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia","volume":"2","author":"Ascher-Svanum H","year":"2008","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, et al.. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008, 2:67-77.","journal-title":"Patient Prefer Adherence"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1411.5067","article-title":"Storage of gold nanoclusters in muscle leads to their biphasic in vivo clearance","volume":"11","author":"Zhang XD","year":"2015","unstructured":"Zhang XD, Luo Z, Chen J, et al.. Storage of gold nanoclusters in muscle leads to their biphasic in vivo clearance. Small. 2015, 11:1683-90. 10.48550\/arXiv.1411.5067","journal-title":"Small"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1126\/science.8134835","article-title":"New challenges in biomaterials","volume":"263","author":"Peppas NA","year":"1994","unstructured":"Peppas NA, Langer R. New challenges in biomaterials. Science. 1994, 263:1715-20. 10.1126\/science.8134835","journal-title":"Science"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.17226\/9942","article-title":"Bridging Disciplines in the Brain, Behavioral, and Clinical Sciences","year":"2000","unstructured":"Bridging Disciplines in the Brain, Behavioral, and Clinical Sciences. Pellmar TC, Eisenberg L (ed). The National Academies Press, Washington, DC; 2000. 10.17226\/9942"},{"key":"ref95","article-title":"A User Guide to the Innovative Medicines Initiative (IMI). First Edition","year":"2020","unstructured":"A User Guide to the Innovative Medicines Initiative (IMI). First Edition. European Commission, Luxembourg City, Luxembourg; 2020."},{"key":"ref96","unstructured":"National Center for Advancing Translational Sciences. Accessed. May 19, 2025: https:\/\/ncats.nih.gov\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373327-the-impact-of-drug-delivery-systems-on-pharmacokinetics-and-drug-drug-interactions-in-neuropsychiatric-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T17:17:29Z","timestamp":1749403049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373327-the-impact-of-drug-delivery-systems-on-pharmacokinetics-and-drug-drug-interactions-in-neuropsychiatric-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":96,"URL":"https:\/\/doi.org\/10.7759\/cureus.85563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}